Industry Trend Analysis - Delivery Technology Will Aid Cancer Vaccine Success - APR 2017


B MI View: Employing a delivery technology to the cancer vaccine galinpepimut-S may increase its efficacy in targeting the hard-to-reach WT1 immuno-oncology target. With WT-1 being present in a large percentage of cancer cells, and not in health y cells , a successful product will be lucrative. Th is agreement strengthens Advaxis and its technology, which is partnered with numerous big pharma companies, and could aid in bring ing success to the struggling cancer vaccine segment.

Advaxis has granted Sellas Life Sciences a licence to develop a novel cancer immunotherapy agent using Advaxis' proprietary Lm-based antigen delivery technology with Sellas' patented WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S).

Under the terms of the collaboration, Advaxis will conduct all preclinical activities required for an IND filing. Thereafter, Sellas will be responsible for all clinical development and commercial activities. Advaxis will receive future payments of up to USD358mn from Sellas if certain development, regulatory, and commercial milestones are met. Following any regulatory approval of the product candidate emanating from this particular programme, Sellas has agreed to pay Advaxis single-digit to low double-digit royalties based on worldwide net sales upon commercialisation.

Advaxis' Partnerships Aid Out-Performance
Normalised Equity Performance Advaxis/NASDAQ Biotechnology Index, 2016-2017
Source: Bloomberg, BMI

This article is part of our Americas coverage. To access this article subscribe now or sign up for free trial